Paper Details

  1. Home
  2. Paper Details

Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?

Author: AkinCem, ArockMichel, ValentPeter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Indolent systemic mastocytosis (ISM) is the most prevalent form of systemic mastocytosis. Many patients with ISM have symptoms related to mast cell (MC) mediators. Conventional treatment with mediator-targeting drugs or MC-stabilizing agents can control symptoms, but some patients remain refractory. Tyrosine kinase inhibitors directed against KIT and other key kinases expressed in neoplastic MCs are potential novel therapies. Midostaurin and avapritinib are the two most effective and well-studied KIT-targeting drugs currently available. Other KIT-targeting drugs, such as imatinib or masitinib, are less effective or noneffective against KIT D816V and are thus recommended for use only in patients with other KIT mutant forms (noncodon 816 mutations) or with wild-type KIT. This review summarizes the current state of ISM treatment with tyrosine kinase inhibitors, with an emphasis on treatment responses and potential adverse effects.
Paper Details　
Original Abstract of the Article :
Indolent systemic mastocytosis (ISM) is the most prevalent form of systemic mastocytosis. Many patients with ISM suffer from mast cell (MC) mediator-related symptoms. In a small number of patients, hematologic progression is seen in the follow-up. In some patients with ISM, symptoms arising from MC-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaci.2022.04.020

データ提供：米国国立医学図書館（NLM）

Tyrosine Kinase Inhibitors for Indolent Systemic Mastocytosis: A New Oasis in the Desert of Disease

This study explores the use of tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis (ISM), a rare condition characterized by an overgrowth of mast cells in the body. Imagine a desert with a hidden oasis that holds the key to healing. This research explores the potential of tyrosine kinase inhibitors to provide relief for patients with ISM.

Tyrosine Kinase Inhibitors: A Potential Oasis for Mastocytosis

The study highlights the potential of tyrosine kinase inhibitors, such as midostaurin and avapritinib, for treating ISM. These drugs target the KIT receptor, which is often mutated in ISM. This is like discovering a hidden spring in the desert, offering a source of healing and relief for those suffering from ISM. The study acknowledges that while these drugs show promise, they also have potential side effects, and their use should be carefully considered and monitored.

Mastocytosis Treatment: Seeking Relief in the Desert of Disease

This study offers hope for patients with indolent systemic mastocytosis. It's like finding a new path through the desert, leading to a brighter future. The research into tyrosine kinase inhibitors provides valuable insights into potential treatments for this challenging condition. It emphasizes the importance of continued research and development of new and effective therapies for rare diseases.

Dr.Camel's Conclusion

This study delves into the world of tyrosine kinase inhibitors as a potential treatment for indolent systemic mastocytosis. It's like finding a precious pearl in the vast and desolate desert of rare diseases. The study highlights the promise of these drugs, but also acknowledges their potential side effects, emphasizing the need for careful consideration and monitoring. The quest for effective treatments for rare diseases continues, and this study provides valuable insights into the potential of tyrosine kinase inhibitors for ISM.

Date :
  1. Date Completed 2022-06-08
  2. Date Revised 2022-07-19
Further Info :

Pubmed ID

35487307

DOI: Digital Object Identifier

10.1016/j.jaci.2022.04.020

Related Literature

Article Analysis
・Effects of avapritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.